Clinical Trials Sponsored by Falu Hospital

Total 99917 results

Falu Hospital

Completed

Colposcopic Impression in a Birth Cohort Previously Eligible for HPV-vaccination

Cervical Cancer | HPV

Sweden
Falu Hospital

Completed

Feasibility of Sending a Direct Send HPV Self-sampling Kit to Long-term Screening Non-attenders

Cervical Cancer | HPV

Sweden
Joakim Dillner
Karolinska Institutet; Danderyd Hospital; Falu Hospital

Completed

Convalescent Plasma for Treatment of COVID-19

Covid19

Sweden
Västernorrland County Council, Sweden
Falu Hospital; University of Gavle; Västervik Hospital

Recruiting

The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting

Breast Cancer | Chemotherapy-induced Nausea and Vomiting | Colorectal Cancer | Bladder Cancer | Testicular Cancer

Sweden
Nalu Medical, Inc.

Recruiting

Clinical Study of a Micro-Implantable Pulse Generator for the Treatment of Peripheral Neuropathic Pain (COMFORT 2) (COMFORT 2)

Chronic Pain | Peripheral Neuropathy | Peripheral Neuralgia

United States
Nalu Medical, Inc.

Recruiting

Clinical Study Of a Micro-Implantable Pulse Generator For The Treatment of Peripheral Neuropathic Pain (COMFORT)

Chronic Pain | Peripheral Neuralgia

United States
Nalu Medical, Inc.

Completed

Spinal Cord Stimulation in the Treatment of Chronic, Intractable Pain Using the Nalu™ Neurostimulation System (nPower™-US)

Pain, Chronic | Pain, Intractable | Pain, Back

United States
Dr. Falk Pharma GmbH

Recruiting

Different Doses of ZED1227 vs. Placebo in NAFLD (NormaliZED)

NAFLD | Liver Fibrosis

Germany
Dr. Falk Pharma GmbH

Recruiting

Norursodeoxycholic Acid vs. Placebo in NASH

Nonalcoholic Steatohepatitis

Austria
Inonu University
Burcu Talu

Enrolling by invitation

The Effect of Core Exercises on Pelvic Dysfunction, Sexual Dysfunction, Pain, Sleep Quality and Quality of Life in Women With Fibromyalgia

Fibromyalgia

Turkey
Dr. Falk Pharma GmbH

Completed

Mesalazine Oral Suspension in Active Eosinophilic Esophagitis

Eosinophilic Esophagitis

Switzerland
Dr. Falk Pharma GmbH

Completed

Budesonide for Induction of Remission in Incomplete Microscopic Colitis

Incomplete Microscopic Colitis

Germany, Sweden
Dr. Falk Pharma GmbH

Terminated

Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

France, Germany
Dr. Falk Pharma GmbH

Completed

Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis

Proctitis

Germany
Dr. Falk Pharma GmbH

Completed

Pharmacokinetic Investigation of UDCA in Bile and Serum

Healthy

Netherlands
Burcu Talu

Completed

Effects on Pes Planus Exercise Training Mixed With Play on Pre-school Children

Flat Foot | Pes Planus | Femoral Anteversion

Turkey
Dr. Falk Pharma GmbH

Terminated

Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis

Radiation Proctitis

Germany
Dr. Falk Pharma GmbH

Recruiting

norUrsodeoxycholic Acid vs Placebo in PSC

Primary Sclerosing Cholangitis

Austria, Germany
Dr. Falk Pharma GmbH

Completed

Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis (EOS-2)

Eosinophilic Esophagitis

Germany
Dr. Falk Pharma GmbH

Completed

Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea (ERASE)

Traveler's Diarrhea

Ecuador, Guatemala, India
Dr. Falk Pharma GmbH

Completed

Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis

Lymphocytic Colitis

Germany
Dr. Falk Pharma GmbH

Completed

Budesonide 9 mg Capsules in Active UC (TOPICAL-1)

Colitis, Ulcerative

Germany
Dr. Falk Pharma GmbH

Terminated

Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis

Diverticulitis

United States
Dr. Falk Pharma GmbH

Completed

Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis (EOS-1)

Eosinophilic Esophagitis

Germany
Dr. Falk Pharma GmbH

Completed

TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)

Active Ulcerative Colitis

Germany
Dr. Falk Pharma GmbH

Completed

Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled Study

Colonic Diverticulosis

Germany
Dr. Falk Pharma GmbH

Completed

OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis

Ulcerative Colitis

Germany
Dr. Falk Pharma GmbH

Completed

Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease (TRUST-2)

Crohn´s Disease

Germany
Dr. Falk Pharma GmbH

Recruiting

Different Doses of Naronapride vs. Placebo in Gastroparesis (MOVE-IT)

Gastroparesis

Belgium
Dr. Falk Pharma GmbH

Completed

Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2) (PROTECT-2)

Ulcerative Colitis

Germany
Dr. Falk Pharma GmbH

Completed

Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

Germany
Dr. Falk Pharma GmbH

Completed

Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis

Autoimmune Hepatitis

Germany
Dr. Falk Pharma GmbH

Completed

Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis

Uncomplicated Diverticulitis

Germany
Dr. Falk Pharma GmbH

Terminated

Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis

Diverticulitis

Germany
Dr. Falk Pharma GmbH

Terminated

Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis (PROTECT-1)

Ulcerative Colitis

Germany
Dr. Falk Pharma GmbH

Completed

Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis (NUC-3)

Primary Sclerosing Cholangitis

Austria, Germany, Norway
Dr. Falk Pharma GmbH

Completed

Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD)

Oral Chronic Graft vs Host Disease

Germany, Israel
Dr. Falk Pharma GmbH

Completed

Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis

Eosinophilic Esophagitis

Germany
Dr. Falk Pharma GmbH

Completed

9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease

Crohn´s Disease

Germany
Dr. Falk Pharma GmbH

Completed

Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)

Crohn's Disease

Germany
Dr. Falk Pharma GmbH

Completed

Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis

Collagenous Colitis

Germany
Dr. Falk Pharma GmbH

Completed

Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)

Colitis, Ulcerative

Germany
Dr. Falk Pharma GmbH

Completed

Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine

Crohn's Disease

Austria, Germany
Dr. Falk Pharma GmbH

Completed

Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)

Recurrence | Colitis, Ulcerative

Germany
Skane University Hospital
The Swedish Research Council; Uppsala University Hospital; Falu Hospital; Gävle... and other collaborators

Completed

Vacuum Assisted Wound Closure (VAWC) and Mesh Mediated Fascial Traction

Fascial Closure | Open Abdomen

Sweden
Falo, Louis, MD

Active, not recruiting

Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) (MNA-D)

Cutaneous T Cell Lymphoma

United States
Rafa Laboratories
Dr. Falk Pharma GmbH

Completed

Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation

Graft Vs Host Disease

Israel
Sally Falk

Completed

Visual Feedback With Optical Sensing - A Feasibility Study (ROSS-LC)

Lung Cancer

United Kingdom
Sally Falk

Unknown

Simultaneous CBCT Acquisition During Arc Radiotherapy (SCART)

Lung Cancer | Prostate Cancer

United Kingdom
Technische Universität Dresden
Dr. Falk Pharma GmbH

Completed

Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation

Leukemia | Graft-Versus-Host Disease

Germany

3

Subscribe